Nexalin Technology, Inc. (NASDAQ:NXL – Get Free Report) VP Carolyn Hamby Shelton bought 6,000 shares of the stock in a transaction that occurred on Wednesday, March 12th. The stock was bought at an average cost of $2.20 per share, for a total transaction of $13,200.00. Following the completion of the purchase, the vice president now directly owns 30,000 shares of the company’s stock, valued at $66,000. This represents a 25.00 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.
Nexalin Technology Stock Performance
Shares of Nexalin Technology stock opened at $2.15 on Friday. The stock has a market capitalization of $28.60 million, a price-to-earnings ratio of -3.36 and a beta of 4.33. The company has a fifty day moving average of $2.85 and a 200-day moving average of $2.48. Nexalin Technology, Inc. has a 52-week low of $0.35 and a 52-week high of $4.49.
Nexalin Technology (NASDAQ:NXL – Get Free Report) last released its quarterly earnings data on Friday, March 14th. The company reported ($0.28) earnings per share for the quarter. Nexalin Technology had a negative net margin of 3,407.98% and a negative return on equity of 187.59%. The company had revenue of $0.03 million for the quarter.
Wall Street Analysts Forecast Growth
View Our Latest Stock Report on NXL
Institutional Investors Weigh In On Nexalin Technology
A number of large investors have recently modified their holdings of NXL. Kingsview Wealth Management LLC purchased a new position in Nexalin Technology during the 4th quarter valued at about $28,000. Jane Street Group LLC bought a new position in shares of Nexalin Technology during the fourth quarter valued at approximately $28,000. Northern Trust Corp bought a new stake in shares of Nexalin Technology in the 4th quarter worth approximately $36,000. XTX Topco Ltd purchased a new stake in shares of Nexalin Technology in the 4th quarter worth approximately $46,000. Finally, Drive Wealth Management LLC bought a new position in Nexalin Technology during the 4th quarter valued at approximately $55,000. Institutional investors own 0.65% of the company’s stock.
About Nexalin Technology
Nexalin Technology, Inc, a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. The company designs and develops Generation 2 and Generation 3, that is in clinical trials for the treatment of substance abuse issues related to opiate, cocaine, alcohol abuse, alzheimer's disease, and dementia.
Featured Stories
- Five stocks we like better than Nexalin Technology
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- Ignore Reports, Apple Won’t Install Starlink with iOS 18.3
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- Casey’s Uptrend Remains Strong—New Highs on the Horizon
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Taiwan Semiconductor’s Huge U.S. Move—Stock Impact Ahead
Receive News & Ratings for Nexalin Technology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nexalin Technology and related companies with MarketBeat.com's FREE daily email newsletter.